TRIB2 and small cell lung carcinoma: This study revealed for the first time a possible molecular mechanism whereby TRIB2 overexpression contributed to Cisplatin-resistance by downregulating CEBPA protein levels in SCLC cells, and also suggested a potential therapeutic target for further study to overcome chemo-resistant SCLC.